Instrument NameNovo Nordisk A/S ADRInstrument Symbol(NVO-N)

Instrument ExchangeNYSE

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

This strategic play will take time to pay off, but it could keep growth going.

Telemedicine once seemed like it was going to revolutionize healthcare.

No need to break the bank to get in on these excellent companies.

The company is looking especially good after some bad news coming from a rival.

An investment in these players today could score a big win down the road.

The company had a dispiriting update to offer about an investigational drug.

The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug.

Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.

The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock.

Lilly just lowered the price of Zepbound.

Could this beaten-down stock turn things around in the near future?

Novo Nordisk (NVO) is warning about a growing shortage of its popular weight loss drug Ozempic. The ...

There's at least one key common denominator here: tremendous growth prospects.

This competitive showdown just saw one of the players hit a couple of bumps.

The addressable market for the treatments could potentially contract significantly.

Some insurers don't cover Lilly's obesity drug. The company just gave patients a way around that problem.

Shareholders don't have too much to fear -- yet.

A high-profile tech giant has led this high-risk group of companies

Its GLP-1 medicines are just one reason why it could threaten Novo Nordisk.

There are no certainties in equity markets, but these stocks look highly likely to deliver outsized returns.

Ozempic remains on top in the GLP-1 drug market -- but for how long?